<DOC>
	<DOCNO>NCT02042248</DOCNO>
	<brief_summary>The purpose study : - find intensity duration immune response multiple injection investigational study product AGS-004 make one 's dendritic cell one 's strain HIV ; - understand change body 's HIV DNA , HIV-1 RNA peripheral rest CD4+ cell prior follow administration AGS- 004 . - find low level HIV virus detectable standard HIV RNA assay decrease follow administration AGS-004 . - find safe give individual HIV multiple injection AGS-004 make person 's dendritic cell strain HIV . - find administration AGS-004 decrease amount latent HIV infection rest CD4 cell</brief_summary>
	<brief_title>A Phase I/II Study Evaluate Immunologic Response Virologic Impact AGS-004</brief_title>
	<detailed_description>This phase I/II , single-site , pilot study kinetics immunological response virological impact AGS-004 administer participant durable viral suppression ART initiate acute ( AHI ) chronic HIV infection ( CHI ) . Patients screen eligibility Step 1 . Those meeting study eligibility successful production Argos ( AGS ) -004 product enter Step 2 administration AGS-004 . All participant continue ART throughout study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Confirmation HIV1 infection : Chronic HIV infection ( CHI ) define documentation positive HIV test result license ELISA test kit confirm Western blot Multispot HIV1/HIV2 assay prior screening . HIV culture , HIV antigen , plasma HIV RNA , second antibody test method ELISA acceptable alternative confirmatory test . Acute HIV infection ( AHI ) define negative indeterminate enzyme immunoassay ( EIA ) negative HIV RNA test within 45 day reproducibly detectable plasma HIV RNA amplification method . Participants AHI arm study must initiate ART within 45 day AHI diagnosis Ages ≥ 18 &lt; 65 year old Stable ART regimen ≥ 6 month prior Screening ( Visit 1 ) NOTE : The ART regimen define current treatment guideline . Participants may one change ART regimen tolerance , change guideline , dose simplification . On potent antiretroviral therapy , define least 2 nucleoside/nucleotide reverse transcriptase inhibitor plus nonnucleoside reverse transcriptase inhibitor , integrase inhibitor , protease inhibitor . Other potent fully suppressive antiretroviral combination consider casebycase basis . Prior change elimination medication easier dose schedule , intolerance , toxicity permit . All participant must continue cART throughout study . Plasma HIV1 RNA detect limit conventional assay ( limit detection determine assay employ : 75 , 50 , 40 , 20 copies/mL ) ≥ 1 year A single unconfirmed plasma HIV RNA &gt; limit detection &lt; 1000 c/mL allow subsequent assay limit detection ; none 6 month precede study screen visit . Plasma HIV1 RNA &lt; 50 copies/mL screening ( Visit 1 ) CD4 cell count ≥ 350 cells/mm3 screening ( Visit 1 ) Availability adequate sample frozen plasma ( may thaw refrozen ) draw 90 day ( preferably within 30 day ) start ART , OR adequate frozen sample HIV p24 antigenpositive culture supernatant obtain culture rest CD4+ T cell . Note : The VL document preART HIV plasma sample must ≥8,000 copies/ml commence ART regimen ( abstract medical record ) . If viral load measurement associate preART HIV plasma sample , another preART VL measurement 8,000 copies/ml use accept sample AGS004 manufacturing . No history autoimmune disease autoimmune manifestation No active HCV infection ( measureable HCV RNA ) within 90 day eligibility visit ( visit 3 ) . No active HBV infection ( measureable HBV DNA HBVsAg+ ) within 90 day eligibility visit ( visit 3 ) . Ability willingness participant give write informed consent Able willing provide adequate locator information Ability willingness communicate effectively study personnel ; consider reliable , willing , cooperative term compliance Protocol requirement Adequate vascular access leukapheresis Able willing receive Intradermal ( ID ) injection without difficulty All female study participant childbearing potential must agree participate conception process , , participate sexual activity could lead pregnancy , female participant partner must agree use least two reliable form contraception least 21 day prior study entry 12 week last dose study drug product : Acceptable form contraception include follow : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide Intrauterine device ( IUD ) Hormonal birth control drug give pill , shot , place skin Tubal ligation NuvaRing Potential participant must adequate organ function indicate follow laboratory value : System/Laboratory Value : Hematological : Absolute neutrophil count ( ANC ) : ≥1,500/mcL Platelets : ≥125,000/mcL Hemoglobin : ≥12g/dL Coagulation : Prothrombin Time INR : ≤1.5x upper limit normal ( ULN ) Chemistry : K+ level : Within normal limit Mg++levels : ≥1.2 mEq/L &lt; 1.5 x ULN Glucose : Screening serum glucose ( fast nonfasting ) &lt; 120 mg/dl Albumin : ≥3.3 g/dL Renal : Serum creatinine calculate creatinine clearance : ≤1.5 x upper limit normal ( ULN ) OR ≥ 60mL/min potential participant creatinine level &gt; 1.3 x institutional ULN Hepatic : Serum total bilirubin : Total bilirubin &lt; 1.8 time upper limit normal range , unless history Gilbert 's disease deem related treatment atazanavir . If total bilirubin elevate , direct bilirubin must &lt; 2 time ULN range . AST ( SGOT ) ALT ( SGPT ) : ≤ 2.5 X ULN Alkaline Phosphatase : ≤ 2.5 X ULN NOTE : Creatinine clearance calculate per institutional standard . Exclusion Criteria HIV2 antibody positive absence positive HIV1 Western Blot measure Screening Visit ( Visit 1 ) . Untreated syphilis infection ( define positive rapid plasma reagin ( RPR ) without clear documentation treatment ) . Received infusion blood product , immune globulin , hematopoetic growth factor within 90 day prior study entry . History lymph node irradiation dissection . Use follow within 90 day prior entry : immunomodulatory , cytokine , growth stimulate factor systemic corticosteroid , cyclosporine , methotrexate , azathioprine , antiCD25 antibody , IFN , interleukins , interleukin2 ( IL2 ) , hydroxyurea , thalidomide , sargramostim ( granulocyte macrophagecolony stimulate factor [ GMCSF ] ) , dinitrochlorobenzene ( DNCB ) , thymosin alpha , thymopentin , inosiplex , polyribonucleotide , ditiocarb sodium , coumadin , warfarin , Coumadin derivative anticoagulant . Use prior HIV vaccine ( prophylactic and/or therapeutic ) within one year screening ( Visit 1 ) . Prior participation AGS004 clinical research study . Treatment interruption ART &gt; 1 month since start ART preART plasma sample drawn For serious illness require systemic treatment hospitalization , participant must either complete therapy clinically stable therapy , opinion site investigator , least 90 day prior entry . Pregnancy breastfeed Any active malignancy may require chemotherapy radiation therapy . Evidence hepatic decompensation cirrhotic participant : history ascites , hepatic encephalopathy , bleed esophageal varix . History clinical evidence significant unstable cardiac disease ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) clinically significant electrocardiogram ( ECG ) abnormality . Any history cardiac rhythm disturbance require medical surgical therapy . Any renal disorder deem clinically significant investigator . History evidence severe illness , malignancy , immunodeficiency HIV , condition would make participant unsuitable study opinion investigator . Compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric illness physical illness , e.g. , infectious disease . Prisoner recruitment participation permit . Known allergy sensitivity component investigational immunotherapy . Use systemic corticosteroid use topical steroid total area exceed 15 cm2 within 30 day prior Screening anticipate need periodic use corticosteroid study . NOTE : For participant receive ritonavir ( booster protease inhibitor ( PI ) part ART regimen , concomitant use oral/systemic/topical/inhaled/intranasal corticosteroid prohibit . Any history acute chronic pancreatitis . If HIV care provider study investigator unable , assess study PI protocol team , construct fully active alternative ART regimen base previous resistance test and/or treatment history . Known psychiatric substance abuse disorder would interfere one 's ability fully cooperate requirement trial . Any investigational antiretroviral agent use CCR5 inhibitor Screening . Active autoimmune disease condition include , limited : Rheumatoid arthritis ( RF positive arthritis current recent flare ) ; Inflammatory bowel disease ; Systemic lupus erythematosis ( clinical evidence confirm ANA &gt; 1:80 ) ; Ankylosing spondylitis ; Hashimoto 's disease ; Scleroderma ; Multiple sclerosis ; Autoimmune hemolytic anemia ( AHA ) ; Immune thrombocytopenic purpura ; , Type I diabetes mellitus ( insulin therapy Type II diabetes permit ) . Participation another investigational clinical research study ( exception antiretroviral treatment trial use FDA approve antiretroviral agent ) use investigational agent within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Acute HIV Infection</keyword>
	<keyword>Chronic HIV Infection</keyword>
	<keyword>AGS-004</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Phase II</keyword>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>ART</keyword>
	<keyword>UNC</keyword>
	<keyword>Argos Therapeutics</keyword>
	<keyword>The CARE Collaboratory AIDS</keyword>
	<keyword>Immunization</keyword>
	<keyword>vaccination</keyword>
</DOC>